A mid-size pharmaceutical company is deciding whether to invest in generative AI to accelerate clinical trial documentation review. Two of its top three competitors have already deployed similar tools and report faster regulatory submission cycles. What is the most useful first step in assessing the competitive landscape before committing to an investment?

Analyzing how competitors' AI adoption is translating into measurable outcomes, and connecting that to the company's own documentation bottleneck, is what turns competitor activity into an actual, defensible investment case — it asks whether the tool is closing a gap this company genuinely has, not just whether rivals are using it. Matching competitors' reported spending dollar-for-dollar copies a number with no evidence that the same spend would close the same gap for this company's specific bottleneck. Waiting until every major competitor has adopted AI treats slow-following as automatically low-risk, but by the time full market adoption happens, competitors may have already locked in the submission-cycle advantage that mattered most. Announcing an AI initiative publicly to reassure investors addresses perception rather than the underlying competitive question, and committing to a direction before any analysis backs it up risks a public promise the data doesn't support. The principle: a competitive landscape assessment should measure competitor moves against your own performance gaps, not benchmark spending levels or issue announcements for their own sake. A solid operational check is whether the analysis can point to a specific bottleneck the investment would fix — if it can't, the case isn't ready yet.